BodyPharm Semaglutide 3mg Multi-Dose Injection Pen

Format: Pre-filled multi-dose subcutaneous injection pen

Concentration: 3mg semaglutide per pen

Excipients: Disodium phosphate dihydrate, propylene glycol, phenol, sterile water

Includes: Disposable needles for single-use administration

Use restriction: Single patient/single research subject use only

Packaging: Boxed pen with tamper-evident seal

Manufacturer: BodyPharm

Research Protocol Overview

Clinical research programs have generally evaluated semaglutide using:

• 
  Once-weekly administration
  
• 
  A gradual dose-escalation strategy to improve gastrointestinal tolerability
  
• 
  Predetermined maintenance doses following the escalation period
  
• 
  Regular monitoring of metabolic outcomes and safety throughout the study
  

These protocols were designed to assess efficacy while reducing gastrointestinal adverse effects during dose escalation.

Research Monitoring

Researchers typically assess:

• 
  Body weight
  
• 
  HbA1c
  
• 
  Fasting blood glucose
  
• 
  Blood pressure
  
• 
  Gastrointestinal tolerability
  
• 
  Laboratory biomarkers
  
• 
  Adverse events
  
• 
  Overall treatment response
  

Storage

• 
  Store according to the manufacturer's recommendations.
  
• 
  Protect from direct sunlight and excessive heat.
  
• 
  Do not freeze.
  
• 
  Do not use if the pen is damaged or if the solution appears cloudy or contains visible particles.
  

Research Status

Semaglutide has been extensively studied in large clinical trial programs investigating obesity, type 2 diabetes, cardiovascular outcomes, and other metabolic conditions. Ongoing research continues to evaluate long-term efficacy and safety across additional therapeutic areas.

Key References

• 
  STEP Clinical Trial Program
  
• 
  SUSTAIN Clinical Trial Program
  
• 
  SELECT Cardiovascular Outcomes Trial
  
• 
  ClinicalTrials.gov Semaglutide Studies
  
• 
  Peer-reviewed publications in the New England Journal of Medicine and other endocrinology journals.

FAQ's

Q: Is this the same as prescription semaglutide (Ozempic/Wegovy)?

A: No. While semaglutide as a molecule is FDA-approved under those brand names for clinical use, this product is a separately manufactured research-grade compound sold strictly for laboratory research — it is not sourced from, affiliated with, or equivalent to the approved pharmaceutical product.

Q: What's the difference between the 3mg and 6mg pens?

A: Both contain the same compound; the 3mg pen offers a lower total concentration per pen, suited to research protocols requiring smaller total volumes or finer dose titration.

Q: Who can purchase this product?

A: This listing is intended for qualified researchers, laboratories, and institutions conducting legitimate scientific research — not for personal or clinical use.

Q: How should the pen be stored?

A: Store according to cold-chain guidelines (refrigerated, protected from light). Refer to the product insert for exact storage specifications, as peptide compounds are typically temperature-sensitive.

Q: What's included in the box?

A: One 3mg multi-dose semaglutide pen, along with disposable needles, with excipient information printed on the packaging.

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist developed by Novo Nordisk and approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). It underpins the STEP clinical trial program, one of the largest research efforts into GLP-1-based weight management.

Key published findings:

• The pivotal STEP 1 trial found 1,961 participants were enrolled, with those receiving once-weekly semaglutide 2.4mg achieving an average weight loss of 14.85% at week 68, compared to 2.41% with placebo. clinicaltrials
• A pooled analysis of the STEP program found semaglutide combined with lifestyle intervention produced significantly greater weight loss than placebo over 68 weeks, with 86.4%, 69.1%, and 50.5% of participants achieving weight loss of at least 5%, 10%, and 15% respectively, alongside improvements in blood pressure, cholesterol, glycemic markers, and inflammatory markers. nihnih
• The STEP 5 trial examined longer-term outcomes and found sustained weight loss was maintained over a 104-week period in 304 participants randomized to semaglutide 2.4mg or placebo. NatureNature
• More recent Phase 3b data from the STEP UP trial found an investigational higher dose of 7.2mg produced a mean weight loss of 21% in adults with obesity without diabetes, with a tolerable safety profile. Applied Clinical Trials Online
• Semaglutide has also been studied beyond weight management — the STEP-HFpEF trial found semaglutide improved symptoms, physical limitations, and exercise function while reducing body weight in patients with obesity-related heart failure with preserved ejection fraction. nih